SLUP-332 / BAM-15 Blend Tablets

SLUP-332 / BAM-15 Blend Tablets Oral Delivery Profile

SLUP-332 / BAM-15 Blend Tablets represents an advanced oral delivery system, engineered to survive gastrointestinal degradation and provide systemic biological activity without the need for traditional parenteral injection.

Pharmacological Architecture

Parameter	Value
Molecular Formula	SLUP-332 100mcg + BAM-15 25mg
Molecular Mass	Dual-Phase Tablet
Assay Purity	Multi-Component
Appearance	White bi-layer tablets

Figure 1: SLUP-332 / BAM-15 Blend Tablets GI Tract Dissolution & Absorption

Oral Mechanism of Action

Detailed cascade of actions from ingestion to systemic effect:

1. Combines the oral GLP-1 receptor modulation of SLUP-332 with the mitochondrial uncoupling of BAM-15.
2. SLUP-332 suppresses appetite and slows gastric emptying centrally.
3. BAM-15 simultaneously forces mitochondria to burn stored fat as heat at the cellular level.
4. This dual approach attacks obesity from both the CNS (intake) and cellular (expenditure) sides simultaneously.
5. Bi-layer tablet technology ensures each component releases at its optimal absorption site.

Figure 2: Rate of Oral Systemic Bioavailability

Primary Research Results

• Outcome 1: Represents the absolute pinnacle of combinatorial oral metabolic optimization.
• Outcome 2: Multiplies fat loss outcomes beyond either compound administered individually.
• Outcome 3: Provides a needle-free, orally convenient metabolic research protocol.

Dual-Mechanism Body Composition Research

The SLUP-332/BAM-15 Blend tablet combines two mechanistically distinct compounds targeting body composition from complementary angles. SLUP-332 (a selective androgen receptor modulator) drives anabolic partitioning toward lean tissue accretion, while BAM-15 (a mitochondrial uncoupler) increases basal energy expenditure and fat oxidation. The rationale for combination is based on the principle that maximizing body recomposition (simultaneous fat loss and muscle gain) requires both enhanced muscle protein synthesis and increased lipid substrate utilization.

1. SLUP-332 activates skeletal muscle androgen receptors, upregulating protein synthesis via the mTOR/p70S6K pathway and suppressing myostatin-mediated catabolism.
2. BAM-15 uncouples mitochondrial oxidative phosphorylation, forcing increased fatty acid β-oxidation to maintain cellular ATP production.
3. The increased energy demand from BAM-15’s uncoupling preferentially draws on lipid substrates, while SLUP-332 directs dietary amino acids toward muscle protein accretion.
4. Net effect: nutrient partitioning shifts toward lean mass at the expense of adipose tissue, achieving body recomposition without caloric restriction.
5. The combination avoids the hypermetabolic stress of aggressive uncoupling by using moderate BAM-15 doses paired with anabolic muscle preservation.

Combination Research Rationale

• Synergy Hypothesis: BAM-15’s increased energy expenditure creates a caloric deficit that would normally cause lean mass loss. SLUP-332’s anabolic activity protects and builds lean tissue during this deficit, achieving what neither compound achieves alone.
• Convenience: A single tablet simplifies combination research protocols, ensuring consistent co-dosing and eliminating the variability of separate administration timing.
• Oral Advantage: Both compounds are orally bioavailable small molecules, avoiding the injection burden associated with most peptide-based body composition research.
• Monitoring: Research protocols should include body composition assessment (DEXA preferred), lipid panels, liver enzymes, and hormonal markers (testosterone, LH, SHBG).
• Storage: Store at room temperature in original packaging. Protect from moisture. No reconstitution or refrigeration required.